An international comparative analysis found that the level of biosimilar market sustainability differs between countries, largely due to variances in biosimilar policies and years of experience managing a biosimilar market.
Although many countries have sustainable biosimilar policies to some degree, policies regarding biosimilar education and understanding need to be improved to ensure the market is sustainable long-term, according to an international study published in Frontiers in Pharmacology.
The study aimed to gain understanding about how policies can influence market success across the world and offer possible solutions to support biosimilar sustainability.
“This study proposes a set of elements that should underpin sustainable biosimilar policy development over time in a country,” wrote the authors. "At first, biosimilar policies should guarantee the safety and quality of biosimilars, healthy levels of supply and a level of cost savings. As a country gains experience with biosimilars, policies need to optimise uptake and combat any misconceptions about biosimilars."
Policies from 17 countries were assessed. The list included 3 countries from North America (Canada, Mexico, and the United States), 1 from South America (Brazil), 2 from the Asia-Pacific region (Australia and Japan), 9 from Europe (Belgium, France, Germany, Italy, the Netherlands, Norway, Spain, Switzerland, and the United Kingdom), and 2 Gulf Cooperation Council nations (Saudi Arabia and United Arab Emirates). The broad selection was to ensure that countries with different policy archetypes and different levels of economic development were represented.
Country-specific literature reviews were conducted to identify peer-reviewed articles, official government sources, and other forms of media on biosimilar policies and the results were validated by 23 international and local non-industry experts, and 2 advisory board meetings with the experts.
A framework was developed to assess policy sustainability and utilized a rating system using 5 answer categories:
The main finding was that European countries typically had higher sustainability scores than other countries. This was unsurprising because European countries tend to have more experience with biosimilars and more developed policy frameworks. For example, the European Union and the United Kingdom have about 10 years more experience with biosimilars compared with the United States.
Policies that were considered sustainable included:
However, the authors noted that improvements to policies regarding biosimilar contracting approaches as well as education and understand of biosimilars can be made in all study countries.
One of the issues that arose concerned the perception of a policy’s sustainability. The authors found that some policy areas—like those regarding contracting, prescribing, dispensing, and monitoring—were rated as “sustainable for all stakeholders” in some countries but not in others (Chart).
Click to enlarge
The authors had 4 main takeaways from the results on how countries should implement biosimilar policies:
Reference
Alnaqbi KA, Bellanger A, Brill A, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. Published online August 24, 2023. doi:10.3389/fphar.2023.1188368
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.